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OBJECTIVES The aim of this study was to elucidate whether the response of idiopathic dilated
cardiomyopathy (DCM) patients to -blockers can be predicted by positron emission
tomography with fluorine-18 fluoro-2-deoxyglucose (FDG-PET).
BACKGROUND Patients with DCM often have a poor prognosis, and it is important to predict their response
to -blocker therapy, which may be effective in DCM. However, no accurate methods of
predicting their response have been available.
METHODS In 22 DCM patients with reduced left ventricular (LV) systolic function, FDG-PET was
performed. Uptake in the LV after glucose loading was evaluated based on the average global
percent uptake of the injected dose (G%ID) and the coefficient of variance (CV) in 24
segments of the LV. Uptake during fasting was evaluated semiquantitatively on the basis of
the total uptake score. The -blocker was administered, and LV function was monitored by
echocardiography. The histologic findings were assessed in the 18 patients who underwent
endomyocardial biopsy.
RESULTS The -blocker was effective in the majority of patients whose G%ID after glucose loading was
0.7%, and the sensitivity and specificity of G%ID as a predictor of -blocker efficacy were
83.3% and 90.0%, respectively. Percent CV did not predict efficacy. Four groups, defined on
the basis of the FDG uptake score during fasting and G%ID after glucose loading, had
distinctive histologic findings and outcomes.
CONCLUSIONS It has been shown that FDG-PET is a good predictor for the effectiveness of
-blockers. (J Am Coll Cardiol 2004;43:224–33) © 2004 by the American College of
Cardiology Foundation
Metabolic imaging provides information on damaged myo-
cardial cells different from that provided by myocardial
perfusion imaging, and it is important in assessing the status
of heart failure (HF) (1). Myocardial positron emission
tomography (PET) with fluorine-18 fluoro-2-deoxyglucose
(FDG) has been used to assess myocardial viability in
ischemic heart disease (2), and histologic alterations have
also been reported to be predicted by FDG-PET findings
(3). However, the utility of FDG-PET in heart disease
other than ischemic heart disease has never been demon-
strated. There have been a comparatively large number of
reports on FDG-PET in hypertrophic cardiomyopathy.
Although FDG accumulates in the hypertrophied myocar-
dium in the fasting state, the glucose uptake in the glucose-
loaded state is lower than in that in normal myocardium (4).
By contrast, there have been only a few FDG-PET studies
in idiopathic dilated cardiomyopathy (DCM). Some of
them have shown that FDG-PET is useful in differentiating
between idiopathic DCM and ischemic cardiomyopathy (5)
and that inhomogeneous glucose metabolism predicts a
poor outcome in DCM (6).
Beta-blocker therapy has been recognized as an excellent
treatment for HF, including DCM (7), and the prognosis of
patients in whom -blockers are ineffective is poor. More-
over, -blockers may worsen HF in serious cases, and thus
prudence must be exercised in prescribing them. Prediction
of -blocker efficacy could be useful in planning the
treatment regimen of HF patients, and the histologic
findings have been reported to be useful in predicting the
response to -blocker therapy and outcome of DCM (8,9).
The present study was designed to evaluate myocardial
FDG-PET as a method of predicting both the response to
-blocker therapy in patients with DCM and the histologic
findings.
METHODS
Study population. Twenty-two patients with reduced left
ventricular (LV) systolic function whose LV ejection frac-
tion (LVEF) was 0.45 and who did not have significant
coronary artery stenosis were recruited from Osaka Univer-
From the *Department of Tracer Kinetics and Nuclear Medicine, Osaka University
Graduate School of Medicine, Suita; and †Vice Director General, Osaka National
Hospital, Osaka; ‡Department of Radiology, Graduate School of Medical Science
Kyoto Prefectural University of Medicine, Kyoto; and §Department of Internal
Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita,
Japan.
Manuscript received February 3, 2003; revised manuscript received September 5,
2003, accepted September 9, 2003.
Journal of the American College of Cardiology Vol. 43, No. 2, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2003.09.025
sity Hospital. All patients gave their informed consent to
participate in the study. Patients with diabetes mellitus were
excluded. There were 17 males and 5 females (mean age
41.2  16.8 years). All patients underwent myocardial
FDG-PET. Four of 22 patients had a history of hyperten-
sion; one patient had received doxorubicin therapy 15 years
previously; and one patient had a history of aortic valve
replacement for severe aortic regurgitation because of a
bicuspid aortic valve. Because these complications alone
could not explain the reduction in LV systolic function in
these six patients, all 22 patients were diagnosed with
idiopathic DCM. To obtain the normal FDG uptake
values, four male volunteers were assessed by the same
FDG-PET protocol.
In 17 of the patients, -blocker administration was begun
within five weeks (interval between FDG-PET and the start
of -blocker therapy: 13.8  11.1 days [mean  SD])
before or after FDG-PET imaging, in addition to other
conventional medical therapy, such as angiotensin-
converting enzyme inhibitors and diuretics. In five patients,
the -blocker was started in other hospitals, and when the
patients were transferred to our hospital for control of HF,
the dose of -blocker was increased. Carvedilol (n  18) or
metoprolol (n  4) was administered at an initial dose of
1.25 (or 2.5) mg/day or 5 mg/day, and the dose was
increased every week to a final dose of 20 (or 15) mg/day or
40 (or 60) mg/day.
The PET procedure. The FDG-PET study was per-
formed according to the one-day, three-acquisition protocol
indicated in Figure 1 (10), using a whole-body PET camera
(SET-2400W [Headtome V], Shimadzu Medico Co.,
Kyoto, Japan). Images after overnight fasting (PET-1) and
after oral glucose loading (PET-3) were acquired serially on
the same day. The image for subtraction (PET-2) was
acquired just before the second injection of FDG, and the
true glucose-loading image was prepared by subtracting
PET-2 from PET-3. The Headtome V has 32 rings,
providing 63 tomographic slices at 3.125-mm intervals. The
spatial resolution in the tomographic plane was 4-mm
full-width half-maximum (FWHM) at the center, and the
axial resolution was 5-mm FWHM. Transmission scanning
with rotating germanium-68 line sources was first per-
formed for attenuation correction. After the subject had
fasted overnight for at least 12 h, 370 MBq of FDG was
injected via an antecubital vein. Forty-five minutes later, the
first emission scan (PET-1) was performed, and the patients
were then allowed to have lunch. Within 30 min after lunch,
75 g of glucose was loaded orally, and another 370 MBq of
FDG was injected. The second emission scan (PET-2) was
performed before the second FDG injection, and the third
emission scan (PET-3) was performed 45 min after the
second FDG injection.
Analysis of FDG-PET findings. The transaxial tomo-
graphic FDG-PET images were reconstructed from emis-
sion data by filtered backprojection, using a ramp filter and
a Butterworth convolution filter, and attenuation was cor-
rected by transmission data. The true glucose-loading im-
ages were made by subtracting the PET-2 from PET-3
images, taking the physical decay of 18F into consideration.
The transaxial images were transformed into a series of
short-axis, vertical long-axis, and horizontal long-axis
images.
The short-axis images of true glucose loading were used
to construct a polar map of the LV, and the map was divided
into 24 segments (8 segments for each slice of the basal,
mid, and apical ventricle). Segmental percent uptake of the
injected dose per 100 g tissue (%ID), the indicator of FDG
uptake after glucose loading in each segment, was quanti-
tatively calculated as body weight (60 kg)-corrected %ID,
according to the following equation:
%ID 
Ct  100
Dose  CF  60/BW
 100
where Ct is the myocardial tissue activity of FDG (cpm/ml);
BW (kg) is the patient’s body weight; Dose (MBq) is the
dose of FDG injected; and CF is the calibration factor for
MBq on the curie meter and for counts per minute per
milliliter on the PET images. The calibration factor, as
measured in our institution, was 2.61  105 (cpm/ml/
MBq). Left ventricular global uptake (G%ID) was calcu-
lated as the average of 24 segmental %IDs, and the
dispersion of distribution of FDG was expressed in the form
of the coefficient of variance (CV) of 24 segmental %IDs
(%CV  standard deviation [SD]/mean of segmental
%IDs).
Whenever FDG uptake during fasting was as low as the
counts of the cardiac pool, %ID during fasting could not be
Abbreviations and Acronyms
CV  coefficient of variance
DCM  dilated cardiomyopathy
FDG  fluorine-18 fluoro-2-deoxyglucose
(G)%ID  (global) percent uptake of injected dose
per 100 g tissue
HCFI  histopathologic contractility failure index
HF  heart failure
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
PET  positron emission tomography
SPECT  single-photon emission computed tomography
Figure 1. The one-day, three-acquisition protocol of fluorine-18 fluoro-
2-deoxyglucose (FDG)-positron emission tomography (PET) for fasting
and oral glucose loading. Images after overnight fasting (PET 1) and after
oral glucose loading (PET 3) were acquired serially on the same day. The
image for subtraction (PET 2) was acquired just before the second injection
of FDG.
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calculated accurately from the polar map. For instance, the
cases in which the uptake occurred only in the cardiac pool
and not in the myocardium showed various %ID values, and
those cases could not be differentiated from cases with low
uptake in the myocardium during fasting. Therefore, FDG
uptake during fasting was evaluated by the semiquantitative
method. The LV myocardium on the PET images was
divided into a total of 20 segments: 6 segments each on the
basal, mid, and apical short-axis images and 2 apical
segments on the central vertical long-axis image. Uptake
was then scored from 0 (no uptake) to 3 (high uptake)
points. Uptake of FDG in the fasting images was evaluated
by the total uptake score, which was the sum of the points
for all 20 segments.
Myocardial perfusion scintigraphy. In 19 of the 22 pa-
tients, single-photon emission computed tomography
(SPECT) with technetium-99m-tetrofosmin (n  15) or
thallium-201 chloride (201TlCl) (n  4) was performed
within six weeks of FDG-PET (interval between SPECT
and PET: 11.4 10.4 days). Technetium-99m-tetrofosmin
(370 MBq) or 201TlCl (111 MBq) was injected intra-
venously at rest, and the SPECT images were obtained
60 min or 10 min, respectively, after the injection. The
images were acquired with a three-head gamma camera
(GCA9300A/HG; Toshiba Medico Co., Tokyo, Japan)
equipped with high-resolution, general-purpose collimators.
Each image was reconstructed from projection data acquired
over a 360° elliptical orbit by the filtered backprojection
method and was transformed into a series of short-axis,
vertical long-axis, and horizontal long-axis images. The LV
myocardium on the SPECT images was divided into 20
segments in a similar manner to the FDG-PET images
during fasting. Myocardial perfusion was then scored:
0 (normal); 1 (slightly reduced); 2 (moderately reduced);
3 (severely reduced); or 4 (defect). Myocardial perfusion was
evaluated on the basis of the total defect score, calculated as
the sum of the scores for each of the 20 segments.
Follow-up echocardiography. The response to the
-blocker was evaluated by M-mode echocardiography.
Echocardiography was performed before -blocker therapy
and about one year (12 1.8 months; n 18) after the start
of -blocker therapy, with four exceptions: in one patient it
was stopped because of sinus arrest after four months; one
patient who had a good response to the -blocker was
transferred to another hospital at five months; and two
patients showed no response to the -blocker, despite
treatment for over two years. Left ventricular end-diastolic
and end-systolic dimensions were recorded, and LVEF was
calculated by the Teichholz method (11). Patients whose
LVEF had improved by more than 0.1 at follow-up com-
pared with before treatment were defined as “responders.”
Histologic analysis of myocardium. Coronary angiogra-
phy, study of the cardiac pressure, and endomyocardial
biopsy were performed in 18 of the 22 patients. In 15
Figure 2. Typical examples of grading of the histologic findings (hematoxylin-eosin staining 400). (a) No fibrosis, no muscle bundle fragmentation, and
no myocyte degeneration (histopathologic contractility failure index 0). (b) Severe fibrosis but no degenerative change (scores: fibrosis 3; fragmentation
 3; degeneration  0). (c) Severe muscle bundle fragmentation but mild degeneration (scores: fibrosis  2; fragmentation  3; degeneration  1). (d)
Severe degeneration but no fibrosis (scores: fibrosis  0; fragmentation  0; degeneration  3).
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patients, the biopsy was performed within one month before
or after FDG-PET (interval between FDG-PET and
biopsy: 11.3  7.4 days); in two patients it was performed
in other hospitals (4 and 6 months before FDG-PET); and
in one patient, the myocardial specimen was collected
during LV assist device implantation about one year after
FDG-PET. None of patients had any significant coronary
artery stenosis. Significant stenosis was defined as stenosis
75% in major coronary arteries by the criteria of the
American Heart Association. Asynergy in the apex was
detected by left ventriculography in only one patient, but the
lesion was concluded to be an infarction caused by throm-
boembolism from an LV thrombus, as the coronary artery
was not atherosclerotic. The endomyocardial biopsy speci-
mens were collected from the free wall of the LV with a
biotome and an 8F-long sheath inserted into the LV via the
femoral artery. The specimens were used for histologic
analysis after hematoxylin-eosin staining. Five areas were
examined in each specimen, and the histologic findings were
evaluated on the basis of three pathologic features: fibrosis,
muscle bundle fragmentation, and myocyte degeneration.
Each of the histologic features was scored from 0 (no) to 3
(severe), and the scores were added to obtain the his-
topathologic contractility failure index (HCFI), as reported
by Hirose (9) (Fig. 2).
Statistical analysis. Data are reported as the mean value 
SD, and differences between the two groups (i.e., responders
and nonresponders to -blocker therapy) were assessed
using the nonpaired t test. The likelihood of a response to
the -blocker was assessed by logistic regression analysis.
Correlations between the parametric data and nonparamet-
ric data were assessed by the Spearman rank correlation test.
Differences with a p value of 0.05 were considered
statistically significant.
RESULTS
Response to -blocker therapy. In 12 of the 22 subjects,
the LVEF improved by more than 0.1 after -blocker
therapy, whereas in the other 10 patients, LVEF did not
improve. By definition, the former and latter patients were
responders and nonresponders, respectively. One patient in
whom the -blocker was stopped because of sinus arrest and
one patient in whom the dose of the -blocker could not be
increased because of worsening of HF were included among
the nonresponders. Table 1 summarizes the characteristics,
drugs used for -blocker therapy, laboratory data, and
echocardiographic data of the responders and nonre-
sponders. There were no significant differences in the
Table 1. Characteristics of -Blocker Responders and Nonresponders
Responders
(n  12)
Nonresponders
(n  10) p Value
Age (yrs) 38.9  13.6 43.9  20.4 NS
Gender (M/F) (9/3) (7/3)
-Blocker (carvedilol/metoprolol) (8/4) (10/0)
Days required for dose-up of -blocker 31.9  9.3 (n  9) 56.5  25.5 (n  6) 0.05
During fasting
Plasma glucose (mg/dl) 93.2  8.3 99.2  9.3 NS
IRI (U/ml) 7.3  5.4 3.7  3.2 NS
Free fatty acids (Eq/l) 369.3  175.3 359.5  190.7 NS
After glucose loading
Plasma glucose (mg/dl) 194.1  33.0 192.6  49.8 NS
IRI (U/ml) 107.9  55.5 (n  10) 97.1  42.2 (n  9) NS
Free fatty acids (Eq/l) 161.0  137.4 (n  6) 104.5  45.9 (n  6) NS
Noradrenaline (ng/ml) 0.51  0.39 (n  6) 0.37  0.21 (n  9) NS
PCWP (mm Hg) 9.0  6.4 (n  10) 15.5  6.5 (n  8) 0.05
CI (l/min per m2) 2.9  0.9 (n  11) 2.8  1.1 (n  8) NS
Systolic blood pressure (mm Hg) 104.3  16.0 98.2  16.3 NS
Diastolic blood pressure (mm Hg) 66.2  10.0 60.6  9.9 NS
Heart rate (beats/min) 70.8  17.1 69.7  9.9 NS
Before -blocker therapy
LVDD (mm) 69.3  7.9 69.5  8.2 NS
LVDS (mm) 60.1  9.0 60.9  3.6 NS
LVEF 0.282  0.109 0.263  0.090 NS
%FS 14.4  5.2 12.7  4.9 NS
After -blocker therapy
LVDD (mm) 57.3  8.6 69.9  7.4 0.05
LVDS (mm) 41.1  10.5 61.9  8.9 0.05
LVEF 0.552  0.151 0.249  0.084 0.05
%FS 29.3  9.0 11.8  4.4 0.05
Data are presented as the mean value  SD or number of patients.
CI  cardiac index; %FS  percent fractional shortening; IRI  immunoreactive insulin; LVDD  left ventricular
end-diastolic dimension; LVDS  left ventricular end-systolic dimension; LVEF  left ventricular ejection fraction; NS  not
significant; PCWP  pulmonary capillary wedge pressure.
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plasma levels of substrates and insulin between the two
groups. The days required for dose-up of the -blocker was
significantly longer, and pulmonary artery wedge pressure
was significantly higher in nonresponders than responders.
All of the responders survived, but three the nonresponders
died, one of whom received a heart transplant. There were
no significant differences between responders and nonre-
sponders in the echocardiographic data before -blocker
therapy. By contrast, the G%ID of FDG-PET after glucose
loading was significantly higher in the responders (0.80 
0.27%) than in the nonresponders (0.55 0.20%, p 0.05;
G%ID of normal volunteers: 0.83  0.15%) (Fig. 3a), and
the total defect score on myocardial perfusion SPECT was
lower in responders (13.2  4.7) than in nonresponders
(24.8  10.7, p  0.05) (Fig. 3b). Single logistic regression
analysis revealed that the G%ID of FDG after glucose
loading (p  0.05) and the total defect score of perfusion
SPECT (p  0.05) predicted the response to -blocker
therapy, but the echocardiographic parameters did not.
There were no significant differences between responders
and nonresponders in the %CV of FDG-PET after glucose
loading (14.6  5.5% vs. 19.0  10.6%, compared with
normal subjects: 8.2 1.0%) or the total FDG-PET uptake
scores during fasting (15.1  17.5 vs. 19.0  19.3).
Assessment of the effectiveness of the -blocker in the cases
with G%ID 0.7% of FDG after glucose loading revealed
a sensitivity of 83.3% and a specificity of 90.0%. When
-blocker efficacy was assessed in cases with a total defect
score on myocardial perfusion SPECT of 22, sensitivity
was 100% and specificity was 75.0%. These best thresholds
were determined by using receiver-operating characteristic
(ROC) curves.
Relationship between FDG uptake and histologic find-
ings in myocardium. None of the 18 patients who under-
went myocardial biopsy had significant evidence of accumu-
lation of inflammatory cells to make a diagnosis of acute
myocarditis. Only one patient had myocardial disarray, but
the patient did not have the specific pathologic findings of
Figure 3. The (global) percent uptake of injected dose per 100 g tissue of fluorine-18 fluoro-2-deoxyglucose after glucose loading (a) and the total defect
scores on the myocardial perfusion images (b) of responders and nonresponders. SPECT  single-photon emission computed tomography.
Figure 4. Relation of (global) percent uptake of injected dose per 100 g tissue of fluorine-18 fluoro-2-deoxyglucose on the glucose-loading image (a) and
myocardial perfusion single-photon emission computed tomography (SPECT) total defect score (b) to histopathologic contractility failure index as an index
of histologic severity.
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hypertrophic cardiomyopathy. Little fibrosis was detected in
six of the patients (fibrosis score  0).
The G%ID of FDG in the glucose-loading image sig-
nificantly correlated with the HCFI (0.53, p 0.028)
(Fig. 4a). The G%ID was also significantly correlated with
the fibrosis scores (  0.52, p  0.033) and muscle
bundle fragmentation scores (  0.49, p  0.045).
Although G%ID was not significantly correlated with the
myocyte degeneration scores (  0.10, p  0.679), a
few cases had low G%ID values despite exhibiting little
fibrosis and severe degeneration. There was no relationship
between the %CV of FDG after glucose loading and
HCFI (  0.03, p  0.910). As shown in Figure 4b,
there were no significant correlations between the total
defect score of myocardial perfusion SPECT and HCFI
(  0.49, p  0.060), nor were the total myocardial
Figure 5. Relationship between fluorine-18 fluoro-2-deoxyglucose (FDG) uptake pattern and histologic findings. The patients were classified into four
groups according to global percent of uptake of injected dose (ID) per 100 g tissue of FDG after glucose loading and total FDG uptake score during fasting.
HCFI  histopathologic contractility failure index; OMI  old myocardial infarction.
Figure 6. Vertical long-axis images in two cases of different types. The patient on the left side showed low fluorine-18 fluoro-2-deoxyglucose (FDG) uptake
both during fasting (a) (total uptake score  0) and after glucose loading (b) (global percent uptake of injected dose per 100 g tissue [G%ID] 0.36%), and
a low myocardial perfusion defect score (c) (total defect score  11). This patient had severe fibrosis (Fig. 7a), and the left ventricular ejection fraction did
not improve after -blocker therapy (from 0.20 to 0.20). The patient on the right side had high FDG uptake both during fasting (d) (total uptake score 
47) and after glucose loading (e) (G%ID 0.96%). Myocardial perfusion was also maintained (f) (total defect score  13). Although dilation of the left
ventricle was severe, the left ventricular ejection fraction was improved by the -blocker (from 0.18 to 0.56) to the point where the patient became
symptom-free. Histologic examination revealed severe myocyte degeneration and little fibrosis (Fig. 7b). SPECT  single-photon emission computed
tomography.
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perfusion defect scores significantly correlated with the
fibrosis, fragmentation, or degeneration scores. Figure 5
summarizes the relationship between the FDG uptake
pattern and the histologic findings. The patients were
classified into four groups (A to D), according to the G%ID
of FDG after glucose loading (patients were divided by the
value defined from ROC analysis: 0.7%) and the total FDG
uptake score during fasting (patients were divided by the
mean value: 17) (Fig. 5). Each group had its own charac-
teristic histologic findings.
DISCUSSION
Prediction of effectiveness of -blocker therapy. The
fibrotic pattern of the myocardium (8), serum brain natri-
uretic peptide concentration (12), and findings on nuclear
medical imaging with 123I-meta-iodobenzylguanidine (13)
and 123I-15-(p-iodophenyl)-3-R,S-methylpentadecanoic
acid (14) have been reported as predictors of a response to
-blocker therapy in HF patients, and the results of the
present study indicate that the G%ID of FDG after glucose
loading is a good predictor of -blocker efficacy in DCM
patients. Yokoyama et al. (6) reported that FDG-PET
findings predict cardiac events and improvement in LV
function after medical therapy, including therapy with
diuretics, digitalis, angiotensin-converting enzyme inhibi-
tors, and -blockers. They claimed that the %CV (i.e.,
index of dispersion) of the regional myocardial glucose
utilization rate during oral glucose loading was the most
important index predicting the outcome, but not the average
regional myocardial glucose utilization rate. By contrast, in
the current study, the %CV of the percent uptake of the
dose injected after oral glucose loading did not predict the
efficacy of -blocker therapy. In our study, some patients
with left bundle branch block who had a severe FDG defect
in the septum and a high %CV value showed a good
response. Some patients who had severe fibrosis showed
diffuse low uptake and, as a result, a low %CV value. There
were a few patients with slight fibrosis and severe general-
ized degeneration who did not respond to the -blocker.
These patients may have caused the discrepancy between
the results of the two studies. It is difficult to evaluate the
severity of a disease associated with diffuse damage, such as
DCM, based on an index of dispersion, which reflects
differences in regional damage.
It has been reported that perfusion SPECT is useful in
predicting the outcome of DCM patients (15). In the
current study, we found that the myocardial perfusion
SPECT defect score, as well as the G%ID of FDG-PET,
predicts the efficacy of -blocker therapy. However, there
were some discrepancies between the results of perfusion
SPECT and FDG-PET. First, the perfusion SPECT
defect score is supposed to indicate the extent of fibrosis
(16). However, because the SPECT evaluations are relative,
perfusion SPECT cannot accurately evaluate diffuse damage
and may underestimate its severity. On the other hand,
G%ID, which is not a relative value, was used in the
assessment of FDG-PET. One patient with a low G%ID
despite a low myocardial perfusion defect score did not
improve, and his myocardium was replaced by diffuse
fibrosis (Figs. 6a to 6c, and 7a). Uptake of FDG is affected
Figure 7. Histologic findings in the cases in Figures 6a to 6f, and
8. (a) Severe fibrosis and moderate degeneration. (b) No fibrosis and severe
degeneration. (c) Severe fibrosis and mild degeneration (original magnifi-
cation 400).
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not only by myocardial fibrosis, but also by deterioration of
glucose metabolism, such as glucose intolerance (10). Two
patients who showed low FDG uptake, despite normal
perfusion images, were good responders to -blockers. The
fibrosis is irreversible, but the reduced FDG uptake in such
patients is not always irreversible.
The levels of plasma substrates and insulin are important
factors affecting the uptake of FDG. We confirmed the
absence of any significant differences in levels of glucose,
free fatty acids, and insulin between responders and nonre-
sponders. However, the insulin level was relatively high after
glucose loading, and it has been reported that HF patients
have insulin resistance and exhibit reactive hyperinsulinemia
(17). In addition, in our study protocol, insulin levels were
measured not only after 75-g oral glucose loading, but also
after lunch. These factors may have been responsible for the
increase in insulin level.
The FDG-PET study was performed more than one
week after the start of -blocker therapy in nine patients
(-blocker []: 4 responders, 5 nonresponders). There was
no significant difference in G%ID after glucose loading
between treated patients (-blocker []; 0.52  0.10) and
the other patients (-blocker []; 0.59  0.27) in nonre-
sponders (p  0.591), whereas in responders, the G%ID of
-blocker () patients (0.59  0.34) tended to be lower
than that of -blocker () patients (0.90  0.15, p 
0.051), but not statistical significantly. Wallhaus et al. (18)
showed that glucose utilization remained unchanged after
carvedilol treatment in congestive HF patients. However, in
DCM patients, glucose metabolism might be enhanced by a
metabolic switch (19) and decreased by the beneficial effect
of -blocker therapy in responders.
Relationship between FDG-PET and histologic findings.
Endomyocardial biopsy is performed in DCM patients not
only to rule out secondary cardiomyopathy, such as cardio-
myopathy secondary to amyloidosis, sarcoidosis, or myocar-
ditis, but also to evaluate the severity of myocardial damage
and predict the outcome (20). However, endomyocardial
biopsy is invasive, and because the histologic findings are
based on very small specimens, there is no way to know
whether they are representative of the heart as a whole. We
found that the severity of the histologic findings can be
estimated by G%ID of FDG after glucose loading, and that
the FDG accumulation pattern from fasting to glucose
loading suggests the type of myocardial damage seen histo-
logically. The FDG-PET study allows the state of the entire
heart to be observed. For example, we were able to detect
the regional damage in the lateral and antero-apical walls
(Figs. 7c and 8).
A few reports have described glucose metabolism in the
myocytes in DCM. Taylor et al. (21) reported that a higher
myocardial fatty acid uptake rate in the failing heart is more
than that expected in the normal heart, but with a lower
myocardial glucose uptake rate. On the other hand, it has
been reported that glucose utilization in HF increases
even during fasting, the same as in an infant’s heart (22).
Actually, the results of the current study suggest that
glucose uptake by myocytes in DCM is not uniform. We
classified the subjects into four groups according to their
FDG accumulation during fasting and after glucose loading.
Figure 8. This patient had high fluorine-18 fluoro-2-deoxyglucose (FDG) uptake during fasting (a to c) (total uptake score  33) and a broad, severely
reduced region in the lateral wall on the glucose-loading image (d to f) (global percent uptake of injected dose per 100 g tissue 0.54). The findings on the
perfusion single-photon emission computed tomography (SPECT) image (g to i) (total defect score  35) were similar to those on the FDG-positron
emission tomography image after glucose loading. Histologic analysis revealed severe fibrosis (Fig. 7c). The patient died of heart failure.
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In group A (Fig. 5), whose FDG uptake pattern was simi-
lar to that in normal myocardium, the histologic damage
was mild and the systolic dysfunction was reversible. In
group B, which showed accelerated uptake during fasting
and maintenance of uptake after glucose loading, some
patients had a fibrosis-dominant pattern, but it was milder
than in group C, whereas other patients had little fibrosis
and a large LV (Figs. 6d to 6f, and 7b). Presumably, the
myocytes in the latter patients were in a state in which the
cells were just able to survive, but their contractile function
was impaired. It has been speculated that FDG uptake
during fasting is increased due to strong wall stress by LV
enlargement (23). Most of the patients in this group had a
relatively good outcome. Group C, in which FDG uptake
was reduced both during fasting and after glucose loading,
comprised two subgroups. The first subgroup had diffuse
severe fibrosis and severe degeneration of the remaining
myocardium. One of two patients in this subgroup under-
went heart transplantation, and the other (Figs. 6a to 6c,
and 7a) is waiting for a heart transplant at the stage of New
York Heart Association class III. The second subgroup had
little fibrosis but showed severe degeneration. Although two
of the patients in this subgroup were good responders to
-blockers, one of them died two years after FDG-PET.
Many of the patients in group C showed discrepancies
between their FDG-PET images after glucose loading and
their myocardial perfusion SPECT images. The metabolic
dysfunction in both subgroups apparently preceded the
fibrosis. However, the metabolic dysfunction was fatal in
some cases and not in others. In group D, which showed
increased uptake during fasting, similar to ischemic myo-
cardium, despite low global uptake after glucose loading, the
fibrosis was severe. An example is shown in Figures 7c and
8. It was speculated that FDG accumulation increased in
the remaining ischemic myocardium surrounded by fibrosis
through a mechanism similar to that of the accumulation of
FDG in myocardial infarction (24). Most patients in group
D had intercellular fibrosis, as reported by Yamada et al. (8),
and their diastolic function had deteriorated and resulted in
a poor outcome despite their relatively small LV. In addi-
tion, some patients showed myocardial disarray and severe
lysis or loss of myocytes, reported as post-myocarditis
change. These findings suggest that the etiology in some of
the patients group D might have been myocarditis (25).
Conclusions. Uptake of FDG after glucose loading was a
good predictor of the response to -blockers, and the FDG
uptake patterns during fasting and after glucose loading
provided some indication of the histologic findings.
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